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TO THE EDITOR
Systemic lupus erythematosus (SLE) is
an autoimmune disease that is classi-
cally associated with fatigue, fever, joint
pains, and skin involvement, although
any organ system can be affected.
Almost all patients with SLE experience
cutaneous manifestations at some point
in their disease course, and an addi-
tional population of patients exists who
experience cutaneous lupus but do not
meet the criteria for SLE. Discoid lupus
erythematosus (DLE), a common lupus-
speciﬁc skin manifestation, is often a
source of disﬁgurement and scarring
alopecia. Currently, there are no
Food and Drug Administration (FDA)–
approved therapies for DLE. Treatment
for DLE is empiric; DLE is treated with
broad-spectrum immunosuppressants
that have the potential for deleterious
side effects and often require frequent
monitoring. There is therefore an unmet
need for effective treatments for DLE
with favorable side-effect proﬁles
(Jessop et al., 2000). The IFN signature
has been described in both SLE and
in cutaneous lupus, inviting studies
targeting this pathway for therapeutic
purposes.
Given the signiﬁcantly increased IFN
signature in human DLE lesions (Jabbari
et al., 2014), we hypothesized that
blocking proximal signaling molecules
downstream of the type I and II IFN
receptors may attenuate the disease.
Ligation of these receptors results in the
activation of JAK1 and TYK2 or the
activation of both JAK1 and JAK2 (for
the type I IFN receptor or the type II IFN
receptor, respectively) (Platanias, 2005).
Ruxolitinib is a small-molecule tyrosine
kinase inhibitor with relative speciﬁcity
for JAK1 and JAK2, approved in 2012
for the treatment of myeloﬁbrosis
(Harrison et al., 2012; Verstovsek
et al., 2012). Ruxolitinib was adminis-
tered by oral gavage to female MRL/lpr
mice, prone to spontaneously develop
cutaneous and systemic lupus, before
development of severe skin involve-
ment. This treatment indeed attenuated
the development of severe skin lesions
by the MRL/lpr mice (Figure 1a).
Ruxolitinib-treated mice exhibited sig-
niﬁcantly reduced lesion severity scores
by week 4 of treatment compared with
control treatment (Figure 1b). Histo-
pathologic analysis showed a signiﬁcant
reduction in epidermal hyperplasia and
inﬂammatory inﬁltrate with ruxolitinib
treatment (Figure 1c and d).
The MRL/lpr mouse model system
also exhibits other manifestations of SLE
including autoantibody production,
renal disease, and immune complex
deposition. Assessments of renal endo-
capillary proliferation, crescent forma-
tion, and interstitial inﬂammation did
not identify signiﬁcant differences
between ruxolitinib and vehicle con-
trol–treated mice (Figure 1e). Immune
complex deposition in kidneys was also
unchanged with ruxolitinib treatment as
assessed by staining for IgG and C3
(Figure 1e). Examinations of other lupus
manifestations did not detect any
change with ruxolitinib treatment. Auto-
antibody levels (Supplementary Figure
S1 online), lymphadenopathy, and sple-
nomegaly (Supplementary Table S1
online) showed no consistent differ-
ences between groups. In sum, only
the skin involvement was signiﬁcantly
alleviated in mice that received ruxoli-
tinib compared with those that received
vehicle control.
Prevention of the development of
cutaneous manifestations of lupus with
continued progression of other disease
manifestations was surprising. One
hypothesis that may account for this
difference pertains to the timing of drug
administration. Ruxolitinib treatment
was started when the animals started
to develop the ﬁrst signs of skin disease
and, at this point, had already exhibited
appreciable gross lymphadenopathy,
renal disease, and autoantibody forma-
tion. Ruxolitinib administration may
have been able to curtail these
extracutaneous markers of end-organ
damage if it had been initiated at an
earlier age. Alternatively, a distinct
pathogenic mechanism may be respon-
sible for the cutaneous lupus as
opposed to lupus nephritis. Indeed, it
seems likely that IL-17 is a contributor
to the pathogenesis of lupus nephritis
(Crispín et al., 2008; Zhang et al.,
2009), whereas it is likely playing a
very limited role in discoid lupus
(Jabbari et al., 2014). Further studies
will therefore be required to distinguish
these possibilities.
In order to examine the effects of
ruxolitinib on the IFN response, MRL/lpr
splenocytes were cultured with IFN-α
and -γ along with graded concentra-
tions of ruxolitinib. After 6 hours of co-
culture, expression of IFN signature
genes was assessed (Figure 2 and
Supplementary Figure S2 online). Rux-
olitinib diminished the expression of
IFN response genes (Figure 2a). In
particular, the T-cell chemokines Cxcl9
and Cxcl10, both of which exhibited
relatively high upregulation in response
to IFNs, were abrogated in expression in
the presence of ruxolitinib. Ruxolitinib
therefore decreases the production of
chemotactic signals for T cells.
An assessment of the T-cell inﬁltrate
was performed by counting immuno-
ﬂuorescently stained CD3+, CD4+, and
CD8+ cells (Figure 2b and c). The skin
from ruxolitinib- versus vehicle-treated
mice had signiﬁcantly fewer CD3+ cells
and CD4+ cells. CD8 T cells were a
minor part of the immune inﬁltrate, but
the cumulative data did show
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differences between these groups.
These results indicate that ruxolitinib
was diminishing the immune inﬁltrate
in cutaneous lupus lesions, likely in part
by diminishing the expression of T-cell
chemotactic genes.
In sum, the use of a small-molecule
inhibitor of JAK1 and JAK2, the prox-
imal signaling molecules that transduce
the type I and II IFN signal, attenuated
the development of cutaneous manifes-
tations in a mouse model of lupus.
Interestingly, other manifestations of
SLE were not signiﬁcantly affected,
and a striking speciﬁcity for alleviating
the development of skin lesions was
observed. Previously published data
examining the effects of ablating type I
and II IFN signaling are mixed in their
effects on SLE manifestations (Crow,
2014), although skin manifestations
have not always been well described
in prior studies. Depending on the
mouse model used, genetic deﬁciency
of the type I IFN receptor either
alleviated (Braun and Demengeot,
2003; Santiago-Raber et al., 2003) or
exacerbated (Hron and Peng, 2004) SLE
manifestations. Type II IFN signaling
attenuation, either by genetic ablation
(Peng et al., 1997; Hron and Peng,
2004) or by blocking antibodies (Jacob
et al., 1987), delayed or prevented SLE
manifestations and, in one study,
seemed to mitigate the exacerbated
phenotype seen due to type I IFN
receptor ablation (Hron and Peng,
2004). Much like this last study, we
show that the net effect of inhibiting
both pathways with ruxolitinib resulted
in a favorable response in a lupus end
organ, in this case the skin. Further-
more, the use of a small-molecule
inhibitor offers advantages not currently
possible for antibody treatments includ-
ing adaptation into a topical form
(Fridman et al., 2011). A double-blind
clinical trial testing the efﬁcacy of a
topical form of ruxolitinib has been
shown to have some efﬁcacy in treating
lesions of psoriasis (Punwani et al.,
2012), an autoimmune skin disease
in which IFNs contribute to its
pathogenesis (Lowes et al., 2014).
The MRL/lpr mouse model is notable
for its spontaneous development of
cutaneous manifestations of disease
(Ghoreishi and Dutz, 2010). Although
the MRL/lpr model exhibits many of the
features of human cutaneous lupus
(Furukawa et al., 1984; Kanauchi
et al., 1991; Furukawa, 1997), not all
aspects of the human condition are
replicated, most notable of which may
be the lack of an interface dermatitis as
a predominant histological feature in
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Figure 1. JAK inhibition prevents the development of cutaneous lupus lesions. (a) Gross skin lesions after control vehicle or ruxolitinib treatment. (b) Gross skin
lesions were graded as described in the Supplementary Materials and Methods online biweekly starting at initiation of treatment (week 0), and trend was analyzed
by mixed modeling. ***Po0.001. (c) Periodic acid Schiff (PAS)–stained skin sections are shown for lesional and nonlesional skin in vehicle-treated mice and
representative skin from ruxolitinib-treated mice. Black bar=100 μm. (d) Grading was performed as indicated in the Supplementary Materials and Methods online
for epidermal hyperplasia, inﬂammatory inﬁltrate, and dermal thickening, and is shown by the group and analyzed by ordinal regression versus control lesional
skin. ***Po0.001. (e) Kidneys were harvested at the end of treatment and stained as indicated and described in the Supplementary Materials and Methods online.
Top panels, black bar=20 μm. Bottom panels, white bar=50 μm.
ES Chan et al.
Cutaneous Lupus Prevention with Ruxolitinib
www.jidonline.org 1913
the MRL/lpr model. Further investi-
gations will therefore be required
before large clinical trials addressing
the efﬁcacy of ruxolitinib in human
cutaneous lupus.
The ﬁndings here show that JAK
inhibition prevents the development of
cutaneous lupus, supporting an impor-
tant role of JAK signaling in cutaneous
lupus pathogenesis with a seemingly
diminished role in the pathogenesis of
dysfunction in other lupus end organs.
Greater elucidation of the role of IFN in
cutaneous lupus and DLE development,
as well as the role of JAK/signal trans-
ducer and activator of transcription
(STAT) inhibition, has the potential to
identify new treatments for human DLE,
and our ﬁndings identify JAK1/2 inhibi-
tion as a therapeutic strategy worthy of
further studies.
The Materials and Methods are docu-
mented in the Supplementary Data
online. The institutional animal care
and use committee at the Columbia
University Medical Center approved all
described studies.
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TO THE EDITOR
Sirtuin 1 (SIRT1), an NAD+-dependent
deacetylase (Imai et al., 2000), acts
as a metabolic sensor that functions on
both histone and non-histone proteins
(Leibiger and Berggren, 2006; Li, 2013).
In this study, we ﬁnd that SIRT1 acti-
vation in animals could inhibit Aldara-
induced psoriasiform lesions. Moreover,
SIRT1–STAT3 interaction may serve as
an important mechanism that underlies
this anti-psoriasis process in keratino-
cytes.
A psoriatic mouse model (The proto-
cols were approved by the Animal Care
and Use Committee at Nanjing Uni-
versity) using Aldara cream (5%
imiquimod, 3 M Pharmaceuticals) on
shaved back skin exhibited signs of
erythema, scaling, and thickening, a
psoriasiform phenotype (van der Fits
et al., 2009; Walter et al., 2013). Histo-
logic examination showed epidermal
hyperplasia and parakeratosis (Figure
1a and b). In addition, the marker
for cellular proliferation Ki-67 and the
marker for abnormal differentiation
of keratinocytes Keratin 17 (Fu and
Wang, 2012) were signiﬁcantly incre-
ased in the lesion epithelia (Figure 1d
and e). The manifestations closely
resembled the characteristics of
psoriatic pathology (Supplementary
Figure S1 online).
Interestingly, the severity of the skin
lesion was signiﬁcantly reduced, when
the mice were treated with an SIRT1
activator resveratrol, before and during
Aldara administration. This resulted
in smoother and thinner skins with
decreased scales and erythemas,
compared with the mice treated with
Aldara only. To determine whether
SIRT1 functioned in this process, a
SIRT1 inhibitor EX527 was applied
to the mice in the same manner.
EX527 treatment exacerbated the
psoriasiform symptoms (Figure 1a). The
score of psoriasis area and the severity
index showed a consistent change
(Figure 1c). Histologically, skin lesions
of resveratrol-treated mice showed
reduced epidermal hyperplasia. In com-
parison, increased epidermal hyper-
plasia and acanthosis were observed
in EX527-treated mice (Figure 1b,
Supplementary Figure S2 online). The
changes in Ki-67 and Keratin 17 levels
in the epithelia were consistent with
the histological alterations (Figure 1d
and e, Supplementary Figure S3A–S3C
online). Furthermore, increased CD4+
immunocyte inﬁltration was observed
in the Aldara-induced lesional skins,
which resembled one of the character-
istics of human psoriatic skin tissues.
The inﬁltration of CD4+ immunocytes
was reduced in the resveratrol group
and increased in the EX527 group
(Figure 1f).
Signal transducer and activator of
transcription 3 (STAT3) is a latent cyto-
plasmic transcription factor that regu-
lates cell growth and differentiation in
response to cytokines (Sano et al.,
2008). Excessive activation of STAT3
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